Endometriosis affects an estimated 1 in 10 women and people who menstruate. Despite its prevalence, diagnosis often takes years. Symptoms such as chronic pelvic pain, heavy bleeding, and fatigue are frequently normalized, and definitive diagnosis can require invasive procedures.
At the same time, a broader shift is happening in how menstrual health is understood, particularly in how menstrual blood is viewed within medical research.
Recently, the BBC reported on new research showing that menstrual blood could be used to detect high-risk HPV with sensitivity comparable to clinician-collected cervical samples. While the study focused on cervical cancer screening, its broader significance lies in validating menstrual blood as a clinically useful biospecimen.
This recognition is important beyond HPV testing. It strengthens the scientific foundation for menstrual blood diagnostics more broadly, including applications relevant to inflammatory and gynecological conditions such as endometriosis.
Why this matters for Endometriosis
Endometriosis remains underdiagnosed and under-researched relative to its impact. Long diagnostic delays create physical, emotional, and economic burdens for patients. One of the major challenges is the lack of accessible, non-invasive early detection tools. If menstrual blood can reliably carry biomarkers for viral detection, as demonstrated in the HPV study highlighted by the BBC, it supports the wider premise that menstrual effluent contains measurable biological signals. This is where SENSOPAD fits into the evolving landscape.
SENSOPAD and the momentum behind menstrual blood diagnostics
SENSOPAD is an EU-funded initiative developing sensor-equipped menstrual pads designed to detect biomarkers associated with menstrual health specifically endometriosis.
Rather than requiring sample collection and laboratory processing, SENSOPAD integrates sensing technology directly into a menstrual pad. The goal is to support non-invasive, at-home monitoring aligned with everyday menstrual use.
As menstrual blood gains scientific credibility, reflected in mainstream coverage and increasing research investment, innovations like SENSOPAD gain traction within a maturing ecosystem. Greater validation of the biospecimen itself supports regulatory pathways, investor confidence, and public awareness.
Importantly, menstrual blood diagnostics are still emerging. However, the broader implication is clear: menstrual blood is increasingly being treated as a viable source of diagnostic information. This shift creates a more favorable environment for technologies targeting endometriosis detection and monitoring.
Understanding the broader landscape
For a deeper look at how this fits into the wider FemTech and diagnostic landscape, including startups and research initiatives working with menstrual blood, the analysis published by Future Fem Health provides important context.
Together, these perspectives show that menstrual blood diagnostics are moving from early research into broader clinical and commercial discussion, creating momentum for projects like SENSOPAD focused on improving endometriosis care.